Trevi Therapeutics, Inc.
TRVI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $416,291 | $132,705 | $124,566 | $17,867 |
| - Cash | $34,097 | $32,397 | $12,589 | $36,830 |
| + Debt | $1,032 | $1,338 | $9,178 | $14,629 |
| Enterprise Value | $383,226 | $101,646 | $121,155 | -$4,334 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$47,790 | -$28,583 | -$27,982 | -$32,709 |
| % Margin | – | – | – | – |
| Net Income | -$47,911 | -$29,065 | -$29,152 | -$33,940 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.47 | -0.29 | -0.45 | -1.49 |
| % Growth | -62.1% | 35.6% | 69.8% | – |
| Operating Cash Flow | -$38,256 | -$31,710 | -$28,175 | -$28,946 |
| Capital Expenditures | -$35 | -$137 | -$159 | $0 |
| Free Cash Flow | -$38,291 | -$31,847 | -$28,334 | -$28,946 |